vadimezan has been researched along with Adrenocortical Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertherat, J; Beuschlein, F; Frantsev, R; Hantel, C; Jäckel, C; Lira, R; Mussack, T; Ozimek, A; Ragazzon, B; Reincke, M | 1 |
1 other study(ies) available for vadimezan and Adrenocortical Carcinoma
| Article | Year |
|---|---|
TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; DNA-Binding Proteins; Female; Humans; Interleukin-1 Receptor-Associated Kinases; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Mice, Nude; Nuclear Proteins; Paclitaxel; Proportional Hazards Models; Signal Transduction; Transcriptional Activation; Tumor Necrosis Factor alpha-Induced Protein 3; Tumor Necrosis Factor-alpha; Xanthones; Xenograft Model Antitumor Assays | 2016 |